$ALDX
Aldeyra Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004111 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.249M $11.28M $2.500M
YoY Change 37.08% 12.94% -22.12%
% of Gross Profit
Research & Development $12.23M $44.94M $7.030M
YoY Change 58.35% 82.07% -26.85%
% of Gross Profit
Depreciation & Amortization $62.74K $264.2K -$160.0K
YoY Change -7.55% 369.9% -633.33%
% of Gross Profit
Operating Expenses $12.23M $44.94M $9.540M
YoY Change 58.35% 82.07% -25.64%
Operating Profit -$16.48M -$56.22M
YoY Change 52.19% 54.36%
Interest Expense $406.0K $1.742M -$480.0K
YoY Change -15.88% -8.51% 77.78%
% of Operating Profit
Other Income/Expense, Net -$304.6K -$1.557M
YoY Change -33.62% -3.43%
Pretax Income -$16.79M -$57.78M -$11.77M
YoY Change 48.7% 51.91% -10.56%
Income Tax $0.00 -$480.0K
% Of Pretax Income
Net Earnings -$16.79M -$57.80M -$11.29M
YoY Change 48.7% 53.72% -14.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29 -$1.07
Diluted Earnings Per Share -$288.0K -$1.069M -$291.9K
COMMON SHARES
Basic Shares Outstanding 58.10M 54.04M 38.82M
Diluted Shares Outstanding 58.30M 54.04M

Balance Sheet

Concept 2022 Q1 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $216.9M $229.8M $77.86M
YoY Change 56.65% 195.13% 6.13%
Cash & Equivalents $158.9M $129.4M $77.86M
Short-Term Investments $57.96M $0.00 $0.00
Other Short-Term Assets $5.489M $2.962M $5.200M
YoY Change -36.18% -43.04% 188.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $222.4M $232.8M $83.06M
YoY Change 51.19% 180.22% 10.5%
LONG-TERM ASSETS
Property, Plant & Equipment $41.42K $384.4K $59.93K
YoY Change -28.04% 32.53% -59.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $337.9K $384.4K $293.2K
YoY Change 44.92% 32.53% -16.09%
TOTAL ASSETS
Total Short-Term Assets $222.4M $232.8M $83.06M
Total Long-Term Assets $337.9K $384.4K $293.2K
Total Assets $222.7M $233.1M $83.35M
YoY Change 51.18% 179.71% 10.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.443M $1.020M $381.6K
YoY Change 444.56% 168.34% -52.79%
Accrued Expenses $13.68M $10.75M $8.135M
YoY Change 154.59% 28.47% -31.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $3.700M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $16.35M $11.77M $12.41M
YoY Change 47.34% -5.14% -3.86%
LONG-TERM LIABILITIES
Long-Term Debt $15.59M $15.50M $11.43M
YoY Change 53.7% 35.64% -21.29%
Other Long-Term Liabilities $63.33K $125.2K
YoY Change
Total Long-Term Liabilities $15.59M $15.63M $11.43M
YoY Change 53.7% 36.74% -21.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.35M $11.77M $12.41M
Total Long-Term Liabilities $15.59M $15.63M $11.43M
Total Liabilities $32.00M $27.40M $23.84M
YoY Change 50.96% 14.94% -13.09%
SHAREHOLDERS EQUITY
Retained Earnings -$311.5M -$236.9M
YoY Change 25.49% 18.84%
Common Stock $502.2M $296.4M
YoY Change 19.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $190.7M $205.7M $59.51M
YoY Change
Total Liabilities & Shareholders Equity $222.7M $233.1M $83.35M
YoY Change 51.18% 179.71% 10.37%

Cashflow Statement

Concept 2022 Q1 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$16.79M -$57.80M -$11.29M
YoY Change 48.7% 53.72% -14.21%
Depreciation, Depletion And Amortization $62.74K $264.2K -$160.0K
YoY Change -7.55% 369.9% -633.33%
Cash From Operating Activities -$12.87M -$42.56M -$8.310M
YoY Change -4.44% 13.5% -25.94%
INVESTING ACTIVITIES
Capital Expenditures $16.32K $7.806K $0.00
YoY Change 109.03%
Acquisitions
YoY Change
Other Investing Activities -$58.02M $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$58.03M -$7.806K $0.00
YoY Change 743325.39% -100.03% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $189.8M
YoY Change -100.0% 366.18%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.32K 194.5M 0.000
YoY Change -99.97% 364.17% -100.0%
NET CHANGE
Cash From Operating Activities -12.87M -42.56M -8.310M
Cash From Investing Activities -58.03M -7.806K 0.000
Cash From Financing Activities 23.32K 194.5M 0.000
Net Change In Cash -70.88M 151.9M -8.310M
YoY Change -217.0% 354.45% 16.06%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$42.56M -$8.310M
Capital Expenditures $16.32K $7.806K $0.00
Free Cash Flow -$12.89M -$42.56M -$8.310M
YoY Change -4.38% 13.52% -25.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Assets Current
AssetsCurrent
232752770
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36332
CY2021 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2021 dei City Area Code
CityAreaCode
781
CY2021 dei Local Phone Number
LocalPhoneNumber
761-4904
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
ALDX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
648685384
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58098965
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
104790989
CY2020Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
52858311
CY2021Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2020Q4 us-gaap Assets Current
AssetsCurrent
83059268
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32487
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59925
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
351863
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233310
CY2021Q4 us-gaap Assets
Assets
233137120
CY2020Q4 us-gaap Assets
Assets
83352503
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1019702
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
381638
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229607
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
233310
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11772662
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12409489
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125232
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2021Q4 us-gaap Liabilities
Liabilities
27401597
CY2020Q4 us-gaap Liabilities
Liabilities
23843945
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58081215
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58081215
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38667491
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38667491
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
58081
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
38667
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
500369444
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
296385619
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294692002
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236915728
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57776274
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-37553729
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54042103
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233137120
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83352503
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44936532
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24681301
CY2021 aldx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2020 aldx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
1754265
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11283004
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9985454
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-56219536
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-36421020
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
185363
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
292224
CY2021 us-gaap Interest Expense
InterestExpense
1742101
CY2020 us-gaap Interest Expense
InterestExpense
1904198
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1556738
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1611974
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57776274
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38032994
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-479265
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33965955
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57776274
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-37553729
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5866
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5866
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57776274
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37559595
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
48082317
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7083810
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40716544
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1058516
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
126966
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5866
CY2020 aldx Net Loss
NetLoss
-37553729
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7006857
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
189811611
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4623251
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61529
CY2020 us-gaap Profit Loss
ProfitLoss
-37553729
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1754265
CY2021 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-479265
CY2021 aldx Issuance Of Common Stock Value In Connection With Acquisition Milestone
IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone
2499991
CY2021 aldx Net Loss
NetLoss
-57776274
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2021 us-gaap Profit Loss
ProfitLoss
-57776274
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7108027
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7083810
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
409471
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
566020
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
91231
CY2021 us-gaap Depreciation
Depreciation
264180
CY2020 us-gaap Depreciation
Depreciation
56221
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2239176
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3396507
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
638064
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-426664
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4561449
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5006375
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42555907
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37493455
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5776090
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34800000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7806
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29023910
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189811611
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40716544
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4623251
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1058516
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
61529
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
126966
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194496391
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41902026
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
151932678
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33432481
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44425830
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229790989
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1337083
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1387750
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NATURE OF BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aldeyra Therapeutics, Inc. (Aldeyra, Company, we, us and our) was incorporated in the state of Delaware on August 13, 2004 as Neuron Systems, Inc. On December 20, 2012, the Company changed its name to Aldexa Therapeutics, Inc. and, on March 17, 2014, the Company changed its name to Aldeyra Therapeutics, Inc. Aldeyra, together with its wholly-owned subsidiaries, is developing and commercializing next-generation medicines to i</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mprove the lives of patients with immune-mediated diseases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s principal activities to date include raising capital and research and development activities</span>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – Financial instruments that potentially subject the Company to significant concentrations of credit risk principally consist of cash, cash equivalents and marketable securities, if any. The Company places its cash and cash equivalents and marketable securities with financial institutions which management believes have high credit ratings. As part of its cash and investment management processes, the Company performs periodic evaluations of the credit standing of the financial institutions with whom it maintains deposits.</span>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to deferred and accrued research and development costs, and accounting for income taxes and the related valuation allowance. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span>
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 aldx Investment Maturity Period
InvestmentMaturityPeriod
three months or less
CY2021 aldx Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P90D
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-37600000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5900
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5135016
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5688356
CY2021Q4 us-gaap Cash
Cash
100364523
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4426466
CY2021Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229790989
CY2020Q4 us-gaap Cash
Cash
23494920
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
29363391
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77858311
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
129426466
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54363391
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
2500000
CY2021Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8415560
CY2020Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3944094
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2404145
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4793794
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
557636
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
407163
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2020Q4 aldx End Of Term Charge
EndOfTermCharge
445464
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
199566
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
351232
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1512885
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1323138
CY2021Q4 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
0
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2021Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
594908
CY2020Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
367533
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q4 aldx End Of Term Charge
EndOfTermCharge
703269
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16042500
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
16042500
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2021 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2021 aldx Net Operating Loss Carry Forwards Expiration Year
NetOperatingLossCarryForwardsExpirationYear
2041
CY2021 aldx Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
2041
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
1000000.0
CY2021 aldx Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
2041
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
61308787
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
48273248
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
63740
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
96129
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9200758
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6375229
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
78378
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
78378
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2301117
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
192200
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3906501
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3762247
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
127791
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
94020
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
76923332
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
58775322
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76827203
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58711582
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
96129
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
63740
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18100000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-338924
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-140341
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-479265
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0665
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0506
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0429
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0328
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3135
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2276
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0073
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0585
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0014
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0055
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0128
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
400000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7108027
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7083810
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4608311
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7492474
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
965169
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.40
CY2021 aldx Aggregate Intrinsic Value Granted
AggregateIntrinsicValueGranted
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
316396
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.23
CY2021 aldx Aggregate Intrinsic Value Cancelled Forfeited
AggregateIntrinsicValueCancelledForfeited
2217529
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
634214
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.29
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2450104
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4622870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M15D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1268089
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3134196
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.90
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M14D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1150723
CY2021Q4 us-gaap Share Price
SharePrice
4.00
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7500000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2021Q4 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2021Q4 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0
CY2021Q3 aldx Lease Extended Term
LeaseExtendedTerm
P18M
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
300000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
381053
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
26214
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
354839
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229607
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125232
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
354839
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
381053
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
252477
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
128576
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
0000950170-22-004111-index-headers.html Edgar Link pending
0000950170-22-004111-index.html Edgar Link pending
0000950170-22-004111.txt Edgar Link pending
0000950170-22-004111-xbrl.zip Edgar Link pending
aldx-20211231.htm Edgar Link pending
aldx-20211231.xsd Edgar Link pending
aldx-20211231_cal.xml Edgar Link unprocessable
aldx-20211231_def.xml Edgar Link unprocessable
aldx-20211231_htm.xml Edgar Link completed
aldx-20211231_lab.xml Edgar Link unprocessable
aldx-20211231_pre.xml Edgar Link unprocessable
aldx-ex10_19.htm Edgar Link pending
aldx-ex10_191.htm Edgar Link pending
aldx-ex10_1911.htm Edgar Link pending
aldx-ex23_1.htm Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img123611162_0.jpg Edgar Link pending
img128143050_0.jpg Edgar Link pending
img128143050_1.jpg Edgar Link pending
img128143050_2.jpg Edgar Link pending
img128143050_3.jpg Edgar Link pending
img128143050_4.jpg Edgar Link pending
img128143050_5.jpg Edgar Link pending
img128143050_6.jpg Edgar Link pending
img128143050_7.jpg Edgar Link pending
img128143050_8.jpg Edgar Link pending
img128143050_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending